{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:12:07Z","timestamp":1788505927526,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd015494","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000}}],"reference-count":62,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015494.pub2","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:53:08Z","timestamp":1773849188000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early intervention for high-risk smoldering multiple myeloma (SMM)"],"prefix":"10.1002","volume":"2026","author":[{"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical University; Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[{"name":"Neurological Institute; Changhua Christian Hospital; Changhua 50006 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical University; Taipei Taiwan"},{"name":"Division of Hematology and Oncology, Medical Department; Taipei Tzu Chi Hospital; Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Lun","family":"Huang","sequence":"additional","affiliation":[{"name":"Information Management Office; Tri-Service General Hospital, National Defense Medical University; Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-5168","authenticated-orcid":false,"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical University; Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"20","key":"10.1002\/14651858.CD015494.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","volume-title":"Plasma Cell Dyscrasias","author":"Mateos","year":"2016"},{"issue":"6","key":"10.1002\/14651858.CD015494.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"25","key":"10.1002\/14651858.CD015494.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015494.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/leu.2014.59","article-title":"Serial exome analysis of disease progression in premalignant gammopathies","volume":"28","author":"Zhao","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1002\/14651858.CD015494.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"10.1002\/14651858.CD015494.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/asheducation-2017.1.194","article-title":"Shall we treat smoldering multiple myeloma in the near future?","volume":"2017","author":"Landgren","year":"2017","journal-title":"American Society of Hematology Education Program"},{"issue":"12","key":"10.1002\/14651858.CD015494.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Kim EB Yee AJ Raje N Treatment of smoldering multiple myeloma: ready for prime time? Cancers 2020 12 5 1223 10.3390\/cancers12051223","DOI":"10.3390\/cancers12051223"},{"issue":"7","key":"10.1002\/14651858.CD015494.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD015494.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clinic Proceedings"},{"issue":"12","key":"10.1002\/14651858.CD015494.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD015494.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD015494.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"European Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD015494.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D'arena","year":"2011","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD015494.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD015494.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","article-title":"State of the science in smoldering myeloma: should we be treating in the clinic?","volume":"46","author":"Hill","year":"2019","journal-title":"Seminars in Oncology"},{"issue":"18","key":"10.1002\/14651858.CD015494.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015494.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD015494.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015494.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.clml.2017.06.022","article-title":"Smoldering multiple myeloma: who and when to treat","volume":"17","author":"Mateos","year":"2017","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"7","key":"10.1002\/14651858.CD015494.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"10.1002\/14651858.CD015494.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015494.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1002\/14651858.CD015494.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015494.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/blood-2019-128519","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"134","author":"Bustoros","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD015494.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD015494.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD015494.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"10.1002\/14651858.CD015494.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clinic Proceedings"},{"issue":"22","key":"10.1002\/14651858.CD015494.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0032|cit32","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015494.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD015494.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0036|cit36","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0037|cit37","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0038|cit38","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.1"},{"issue":"7","key":"10.1002\/14651858.CD015494.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0040|cit40","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0041|cit41","unstructured":"Review Manager (RevMan) The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015494.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015494.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e000893","DOI":"10.1136\/bmjgh-2018-000893","article-title":"Synthesising quantitative and qualitative evidence to inform guidelines on complex interventions: clarifying the purposes, designs and outlining some methods","volume":"4","author":"Noyes","year":"2019","journal-title":"BMJ Global Health"},{"issue":"7109","key":"10.1002\/14651858.CD015494.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD015494.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD015494.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","article-title":"Meta-analysis and subgroups","volume":"14","author":"Borenstein","year":"2013","journal-title":"Prevention Science"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0051|cit51","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.1"},{"issue":"4","key":"10.1002\/14651858.CD015494.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction 2014; GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0053|cit53","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"13","key":"10.1002\/14651858.CD015494.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD015494.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0056|cit56","unstructured":"Carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in high- risk smoldering multiple myeloma: a randomized phase II study https:\/\/clinicaltrials.gov\/study\/NCT03673826"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0057|cit57","unstructured":"Daratumumab to enhance therapeutic effectiveness of revlimid in smoldering myeloma (DETER-SMM) https:\/\/clinicaltrials.gov\/study\/NCT03937635"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0058|cit58","unstructured":"A phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma https:\/\/clinicaltrials.gov\/study\/NCT04270409"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0059|cit59","unstructured":"Immuno-PRISM (precision intervention smoldering myeloma): a randomized phase II platform study of select immunotherapies for high-risk smoldering myeloma https:\/\/clinicaltrials.gov\/study\/NCT05469893"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/oncolo\/oyae219","article-title":"Evaluating early intervention in smoldering myeloma clinical trials: a systematic review","volume":"2024","author":"Kakkilaya","year":"2024","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"100869","DOI":"10.1016\/j.blre.2021.100869","article-title":"Smoldering multiple myeloma - Past, present, and future","volume":"52","author":"Mann","year":"2022","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD015494.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.2147\/CMAR.S205623","article-title":"Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancer Management and Research"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:17:40Z","timestamp":1788502660000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015494.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015494.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}